Table 2.
Treatment patterns of patients with bipolar depression across the 5 data sources
| IQVIA DA France | IQVIA DA Germany | IQVIA US Hospital CDM | IQVIA US Open Claims | Beijing Anding | Pooled from 5 databases | |
|---|---|---|---|---|---|---|
| Sample size | 1,184 | 3,773 | 17,321 | 99,672 | 893 | 122,843 |
| Antidepressants, n (%) | 502 (42.4) | 1,077 (28.5) | 3,072 (17.7) | 69,274 (69.5) | 504 (56.4) | 74,429 (60.6) |
| Mood stabilizers, n (%) | 329 (27.8) | 1,070 (28.4) | 2,107 (12.2) | 41,069 (41.2) | 540 (60.5) | 45,115 (36.7) |
| Prescription of drug approved by FDA for bipolar depression, n (%) | 131 (11.1) | 836 (22.2) | 1,307 (7.5) | 35,448 (35.6) | 336 (37.6) | 38,058 (31) |
| Antipsychotics, n (%) | 412 (34.8) | 1,216 (32.2) | 3,100 (17.9) | 57,142 (57.3) | 574 (64.3) | 62,444 (50.8) |
| Second-generation antipsychotics, n (%) | 379 (32) | 1,177 (31.2) | 2,528 (14.6) | 55,203 (55.4) | 559 (62.6) | 59,846 (48.7) |